Drug intelligence / Profile preview

naphazoline + chlorpheniramine + benzalkonium

Development stage
Unknown
Lead developer
Apollo Pharmacy
Modality
Small Molecules
Administration
Ophthalmic, Topical
01

Overview

Naphazoline + chlorpheniramine + benzalkonium is a fixed-dose combination ophthalmic solution used for the temporary relief of symptoms associated with allergic conjunctivitis and eye irritation. **Naphazoline hydrochloride** is a sympathomimetic amine that acts as a potent vasoconstrictor by stimulating alpha-adrenergic receptors, thereby reducing ocular congestion and redness. **Chlorpheniramine maleate** is a first-generation alkylamine antihistamine that provides relief from allergic symptoms such as itching, watering, and puffiness by competitively antagonizing histamine H1 receptors. **Benzalkonium chloride** is a quaternary ammonium compound primarily included in the formulation as a preservative with antimicrobial properties, though it may also serve as an antiseptic in certain topical formulations. This combination is widely available as an over-the-counter (OTC) medication in various international markets, including India and Japan, to treat eye irritation caused by hay fever, pollen, and animal dander.

Brand names
Apollo Pharmacy Eye Drops
Other names
Naphazoline, Chlorpheniramine Maleate & Benzalkonium Chloride Ophthalmic SolutionNaphazoline/Chlorpheniramine/Benzalkonium
02

Targets

ADRA1A (α1A)ADRA2A (α2A)HRH1 (Histamine H1 Receptor)ADRA1B (α1B)

Beyond the preview

Go deeper on naphazoline + chlorpheniramine + benzalkonium.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on naphazoline + chlorpheniramine + benzalkonium.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call